Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Many congratulations to Professor Sir David Weatherall, who was appointed a Knight Grand Cross of the Order of the British Empire (GBE). This is the highest rank in the Order of the British Empire, an honour only bestowed 16 times since 2000.

David Weatherall is a haematologist and clinical researcher whose research has focused on the genetics of blood disorders affecting haemoglobin, particularly thalassaemia. He was the first to describe thalassaemia outside the Mediterranean and his work has led to the eradication of the disease in some parts of the world. Through his work on thalassaemia, David demonstrated for the first time that a gene deletion could cause a human disease. He developed new methods for analysing haemoglobin and measuring the synthesis of alpha- and beta-haemoglobin chains. This provided the first clear evidence of how thalassaemia arises. In addition, David’s work made possible the detection of thalassaemia early in pregnancy, enabling antenatal diagnosis. His characterisation of the mutations causing thalassaemia led to numerous families being offered genetic counselling.

David has won numerous awards, including the Lasker Prize (which ranks alongside the Nobel Prize for Medicine) and was knighted in 1987. This latest honour also recognises his role in establishing in 1989 the first Institute of Molecular Medicine in the UK (now named the MRC Weatherall Institute of Molecular Medicine in his honour) and in developing the WHO consensus for diagnosing and managing genetic disease, with a global impact.

The announcement was made at the Queen's Birthday Honours earlier in the year, and the investiture ceremony took place at Windsor Castle on the 8th of December.

Similar stories

Mechanism behind repair of cancer-inducing mutations discovered

New Nature paper uncovers the precise mechanism behind how the BRCA1 protein detects and engages with DNA breaks in the genome, helping to prevent the development of breast and ovarian cancers.

DNA breakthrough could help identify why some people are more affected by Covid-19

Scientists from the MRC Weatherall Institute of Molecular Medicine have developed a method that allows them to see, with far greater accuracy, how DNA forms large scale structures within a cell nucleus.

New clinical trial for patients affected by blood cancer

Radcliffe Department of Medicine's Professor Adam Mead is leading PROMise, a new clinical trial offering a novel treatment option for patients with a type of blood cancer called myelofibrosis.

Immune cells imperfect at distinguishing friend from foe

When it comes to distinguishing a healthy cell from an infected one that needs to be destroyed, the immune system’s killer T cells sometimes make mistakes. This discovery, described today in the journal eLife, upends a long-held belief among scientists that T cells were nearly perfect at discriminating friend from foe. The results may point to new ways to treat autoimmune diseases that cause the immune system to attack the body, or lead to improvements in cutting-edge cancer treatments.

New funding for early diagnosis research using platelets

Dr Bethan Psaila and her team will investigate the potential of circulating blood platelets for early detection of a range of cancer types.